Notice of Stock Split and Partial Amendment to Articles of Incorporation

Tokyo, Japan and London, UK, 10 May 2018 – Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, announced that at a meeting of the Board of Directors held today, it resolved to conduct a stock split and partially revise the Articles of Incorporation.

1. Purpose of the Stock Split

1.1. To improve the liquidity by reducing the amount per trading unit of investment in Sosei shares.

2. Overview of the Stock Split

2.1. Method of Stock Split

The record date of the stock split will be 30 June 2018 (as the record date falls on a Saturday, the actual date shall be Friday 29 June 2018). Each share of common stock owned by shareholders recorded on the last Register of Shareholders as of record date will be split into four shares.

2.2. Number of Shares to be Increased by the Stock Split

2.2.1. Total number of issued shares before stock split: 19,054,984 shares
2.2.2. Number of shares to be increased by this stock split: 57,164,952 shares
2.2.3. Total number of shares outstanding after stock split: 76,219,936 shares
2.2.4. Total number of authorized shares after stock split: 149,376,000 shares

Note: The total number of issued shares is as of 10 May 2018, and does not include any increase in the number of issued shares that could occur as a result of the exercise of stock acquisition rights.

2.3. Adjustment of Exercise Price of Stock Option

In connection with the announced stock split, the exercise price of stock acquisition rights shall be adjusted as follows after the record date.

	Exercise price (JPY) Before adjustment	Exercise price (JPY) After adjustment
26th Series Stock Acquisition Rights	648	162
27th Series Stock Acquisition Rights	648	162
29th Series Stock Acquisition Rights	4,130	1,033
30th Series Stock Acquisition Rights	4,130	1,033
31st Series Stock Acquisition Rights	1	1
32nd Series Stock Acquisition Rights	12,340	3,085
33rd Series Stock Acquisition Rights	12,340	3,085

34th Series Stock Acquisition Rights	10,746	2,687
35th Series Stock Acquisition Rights	10,746	2,687

3. Stock Split Schedule

3.1. Date of announcement of the record date: 14 June 2018
3.2. Record date: 30 June 2018 (Saturday)
3.3. Effective date: 1 July 2018 (Sunday)

4. Change in the Amount of Stated Capital

4.1. There is no change in the amount of stated capital with respect to the stock split.

5. Partial Amendment to the Articles of Incorporation

5.1. Purpose of the Amendment

Accompanying the stock split, Sosei shall partially revise its Articles of Incorporation to take effect on 1 July 2018 (Sunday) pursuant to Article 184, Paragraph 2 of the Companies Act.

5.2. Content of the Amendment

Article 5 of the current Articles of Incorporation shall be changed to increase the total number of authorized shares in proportion to the stock split ratio.

Before Amendment	After Amendment
(Total number of shares authorized to be issued) Article 5. The total number of shares authorized to be issued of the Company shall be 37,344,000 shares.	(Total number of shares authorized to be issued) Article 5. The total number of shares authorized to be issued of the Company shall be 149,376,000 shares.

Enquiries:

Sosei +44 (0) 7912 892 199
Chris Cargill, Head of Investor Relations and Corporate Communications

Citigate Dewe Rogerson (media advisor) +44 (0) 20 7638 9571
David Dible
Mark Swallow

About Sosei Group Corporation

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators

include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit http://www.sosei.com/en/.